Tag: Small-molecule eIF2B activator and integrated stress response inhibitor

  • ISRIB

    Small-molecule eIF2B activator and integrated stress response inhibitor

    A symmetrical bis-glycolamide that stabilizes the decameric eIF2B holoenzyme, counteracting phospho-eIF2alpha-mediated translational repression and reversing age-related, traumatic, and neurodegenerative cognitive deficits in preclinical models without the pancreatic toxicity of upstream PERK kinase inhibitors.

    Abstract

    ISRIB (integrated stress response inhibitor) is a cell-permeable, brain-penetrant small molecule identified by Sidrauski et al. (2013) at the University of California, San Francisco, through a phenotypic screen for compounds that render cells resistant to the translational consequences of eukaryotic initiation factor 2 alpha (eIF2alpha) phosphorylation [1]. The compound blocks the integrated stress response (ISR) with an IC50 of approximately 5 nM in ATF4 reporter assays, operating downstream of all four eIF2alpha kinases (PERK, GCN2, HRI, PKR) at the level of the guanine nucleotide exchange factor eIF2B [2]. Cryo-electron microscopy studies (Tsai et al. 2018; Zyryanova et al. 2021) demonstrated that ISRIB binds at the symmetry interface of two eIF2B betagammadeltaepsilon tetrameric subcomplexes, acting as a molecular staple that promotes assembly of the catalytically active decameric holoenzyme and allosterically antagonizes the inhibitory effect of phosphorylated eIF2alpha on the nucleotide exchange reaction [3, 4]. The resulting restoration of ternary complex formation and global protein synthesis rates is partial rather than complete, reaching approximately 50 to 70 percent of unstressed control levels even at saturating compound concentrations, a feature that accounts for the favorable safety profile relative to direct PERK kinase inhibitors such as GSK2606414 that produce pancreatic exocrine destruction [5].

    Preclinical pharmacology spans multiple disease-relevant models. In cognition, ISRIB enhances spatial and fear-associated learning in wild-type mice (Sidrauski et al. 2013) [1], reverses cognitive deficits weeks after traumatic brain injury (Chou et al. 2017) [6], restores age-related memory decline and hippocampal neuronal function within days of treatment in aged mice (Krukowski et al. 2020) [7], and rescues synaptic plasticity in a mouse model of Down syndrome [8]. In neurodegeneration, ISRIB prevents neuronal loss in prion-diseased mice without pancreatic toxicity (Halliday et al. 2015) [5] and stabilizes vanishing white matter disease eIF2B mutant complexes to wild-type catalytic activity (Wong et al. 2018) [9]. Additional preclinical activity has been reported in prostate cancer [10], noise-induced cochlear synaptopathy [11], postinfarct atrial fibrillation [12], and amyotrophic lateral sclerosis models [13].

    No human clinical trials of ISRIB itself have been conducted. However, the compound served as the pharmacological prototype for two clinical-stage eIF2B activators: DNL343 (Denali Therapeutics), which completed a Phase 2/3 trial in amyotrophic lateral sclerosis (HEALEY platform trial) without meeting primary endpoints [14], and fosigotifator (Calico/AbbVie), which also failed to demonstrate significant slowing of disease progression in the same platform trial, although an exploratory high-dose arm showed signals on muscle strength preservation [15]. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.